Core Viewpoint - Xinhua Pharmaceutical's stock price has shown a slight increase of 2.65% year-to-date, but has experienced a decline over the past 60 days, indicating potential volatility in its market performance [1][2]. Company Overview - Xinhua Pharmaceutical, established on November 20, 1998, and listed on August 6, 1997, is located in Zibo, Shandong Province. The company specializes in the development, manufacturing, and sales of chemical raw materials, pharmaceutical preparations, and other products [1]. - The company's main business revenue composition includes: 44.36% from tablets, injections, and capsules; 32.11% from raw materials for antipyretic and analgesic drugs; and 23.53% from pharmaceutical intermediates and others [1]. Financial Performance - For the period from January to September 2025, Xinhua Pharmaceutical achieved an operating income of 6.763 billion yuan, representing a year-on-year growth of 0.42%. However, the net profit attributable to shareholders decreased by 25.53% to 256 million yuan [2]. - The company has distributed a total of 1.17 billion yuan in dividends since its A-share listing, with 495 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Xinhua Pharmaceutical was 70,700, a decrease of 7.60% from the previous period. The average circulating shares per person remained at 0 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 3.1337 million shares, a decrease of 275,600 shares from the previous period [3].

Core Insights - Xinhua Pharmaceutical, established in 1998 and listed in 1997, is a significant player in the raw material pharmaceutical industry in China, particularly in the field of analgesics, with a full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion, ranking third among 47 companies in the industry, with the top competitor, Puluo Pharmaceutical, generating 7.764 billion [2] - The net profit for the same period was 267 million, placing Xinhua ninth in the industry, while the leading company, Zhejiang Pharmaceutical, achieved a net profit of 867 million [2] Group 2: Financial Ratios - As of Q3 2025, Xinhua Pharmaceutical's debt-to-asset ratio was 40.72%, down from 42.25% year-on-year, which is higher than the industry average of 27.75% [3] - The gross profit margin for Q3 2025 was 19.17%, a decrease from 23.50% year-on-year, and below the industry average of 35.38% [3] Group 3: Executive Compensation - The chairman, He Tongqing, received a salary of 1.8981 million in 2024, an increase of 285,300 from 2023 [4] - The general manager, Xu Wenhui, earned 1.8081 million in 2024, up by 286,700 from the previous year [4] Group 4: Shareholder Information - As of June 30, 2025, the number of A-share shareholders decreased by 2.48% to 76,500, while the average number of shares held per shareholder increased by 10.89% to 6,442.22 [5] - By September 30, 2025, major shareholders included Hong Kong Central Clearing Limited and various ETFs, with notable decreases in their holdings [5]

山东新华制药股份(00719)绩后跌超3%，截至发稿，跌3.17%，报7.03港元，成交额3116.25万港元。 消息面上，10月24日，山东新华制药股份发布截至2025年9月30日止九个月业绩，营业收入67.63亿元 (人民币，下同)，同比增长0.42%；归属于上市公司股东的净利润2.56亿元，同比下降25.53%；基本每 股收益0.37元。 ...

消息面上，10月24日，山东新华制药股份发布截至2025年9月30日止九个月业绩，营业收入67.63亿元 (人民币，下同)，同比增长0.42%；归属于上市公司股东的净利润2.56亿元，同比下降25.53%；基本每 股收益0.37元。 （原标题：港股异动 | 山东新华制药股份(00719)绩后跌超3% 前三季度归母净利同比下降25.53%） 智通财经APP获悉，山东新华制药股份(00719)绩后跌超3%，截至发稿，跌3.17%，报7.03港元，成交额 3116.25万港元。 ...

（文章来源：每日经济新闻） 每经AI快讯，山东新华制药股份(00719.HK)绩后跌超3%，截至发稿，跌3.17%，报7.03港元，成交额 3116.25万港元。 ...

Core Viewpoint - Xinhua Pharmaceutical's stock has experienced a decline, with a current price of 15.75 yuan per share and a market capitalization of 10.864 billion yuan, reflecting a 2.05% drop on October 27 [1] Financial Performance - For the period from January to September 2025, Xinhua Pharmaceutical reported revenue of 6.763 billion yuan, a year-on-year increase of 0.42%, while net profit attributable to shareholders decreased by 25.53% to 256 million yuan [2] - The company has distributed a total of 1.17 billion yuan in dividends since its A-share listing, with 495 million yuan distributed over the past three years [3] Stock Market Activity - The stock has seen a year-to-date increase of 1.88%, but has declined by 2.84% over the last five trading days, 3.61% over the last twenty days, and 7.89% over the last sixty days [1] - As of September 30, 2025, the number of shareholders decreased by 7.60% to 70,700, with an average of 0 circulating shares per shareholder [2] Shareholder Composition - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.1337 million shares, a decrease of 275,600 shares from the previous period [3] - Other notable shareholders include Southern CSI 1000 ETF and Huaxia CSI 1000 ETF, both of which have also seen reductions in their holdings [3]

Core Insights - The company reported a revenue of 2.124 billion yuan for Q3 2025, representing a year-on-year growth of 6.10% [1] - The net profit attributable to shareholders decreased to 32.4642 million yuan, down 58.74% year-on-year [1] - Basic earnings per share for Q3 2025 were 0.05 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 6.763 billion yuan, reflecting a slight year-on-year increase of 0.42% [1] - The net profit attributable to shareholders for the first three quarters was 256 million yuan, which is a decline of 25.53% compared to the previous year [1] - Basic earnings per share for the first three quarters were 0.37 yuan [1]

Core Viewpoint - Xinhua Pharmaceutical (000756) reported a decline in net profit for Q3 2025 despite a revenue increase, indicating challenges in maintaining profitability amid competitive market pressures [1] Financial Performance - In Q3 2025, the company achieved revenue of 2.124 billion yuan, representing a year-on-year growth of 6.1% [1] - The net profit attributable to shareholders was 32.4642 million yuan, showing a significant year-on-year decline of 58.74% [1] - For the first three quarters of 2025, total revenue reached 6.763 billion yuan, with a modest year-on-year growth of 0.42% [1] - The net profit for the first three quarters was 256 million yuan, down 25.53% compared to the previous year [1] Market Strategy - The decline in net profit is primarily attributed to the company's strategic decision to adjust product prices in response to intense market competition, aiming to consolidate or increase market share [1]

Group 1 - The core viewpoint of the article highlights that Xinhua Pharmaceutical reported a revenue of 2.124 billion yuan in the third quarter, representing a year-on-year increase of 6.10% [1] - The net profit for the third quarter was 32.4642 million yuan, showing a significant year-on-year decline of 58.74% [1] - For the first three quarters, the total revenue reached 6.763 billion yuan, which is a slight year-on-year increase of 0.42% [1] - The net profit for the first three quarters was 256 million yuan, reflecting a year-on-year decrease of 25.53% [1]

山东新华制药股份有限公司 一间 于中 华人 民共 和国成 立的 中外 合资股 份有 限公 司 公 司 章 程 经公司于2025年10月24日召开的2025年第一次临时股东大会审 议通过修订 | | | 第一章 总则 Limited 2 第一条 本公司系依照《中华人民共和国公司法》（简称《公司法》）和 其他有关法律、行政法规成立的股份有限公司。 本公司 1993 年 9 月经山东省经济体制改革委员会以鲁体改生字 （1993）第 66 号文批准确认以定向募集方式设立，1996 年 8 月 经国家经济体制改革委员会以体改生字（1996）116 号文确认为 到香港发行股票并上市的股份有限公司。公司于 1998 年 11 月 20 日在淄博市工商行政管理局重新注册登记，取得公司营业执照。 公司统一社会信用代码：91370300164103727C 公司的发起人为：山东新华制药厂 第二条 根据《公司法》和《中国共产党章程》规定，公司设立中国共产 党的组织，建立党的工作机构，配备足够数量的党务工作人员， 保障党组织的工作经费。公司党组织发挥领导作用，把方向、管 大局、保落实，依照规定讨论和决定公司重大事项。 第三条 公司注 ...